RxDoctor Payments Data

Prudent Marcelin, MD

Family Medicine · Maitland, FLNPI 1013249549

Payments from drug & device makers

$213in general payments, 2019–2025

Across 15 payments — averaging $14.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$54
  • Novo Nordisk$39
  • Almatica Pharma LLC$39
  • Supernus Pharmaceuticals, Inc.$31
  • Amgen$29
  • Pfizer$17
  • plus $5 from 1 others

What the payments were for

  • Food & beverage$20295%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC4$54
Novo Nordisk2$39
Almatica Pharma LLC2$39
Supernus Pharmaceuticals, Inc.2$31
Amgen2$29
Pfizer1$17
Kvk-tech, Inc.2$5

How this compares

$213 in reported general payments places this provider in the 35th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$49,008
Medicare patients
81
Services billed
365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide195$294,799
OzempicSemaglutide130$162,393
EliquisApixaban113$119,403
LinzessLinaclotide83$112,448
JardianceEmpagliflozin55$71,009
FarxigaDapagliflozin Propanediol37$48,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$46,700
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$40,495
Xtampza ErOxycodone Myristate47$39,242
SymbicortBudesonide/Formoterol Fumarate113$32,102
NamzaricMemantine Hcl/Donepezil Hcl31$31,917
RexultiBrexpiprazole17$30,177
VireadTenofovir Disoproxil Fumarate18$22,501
MyrbetriqMirabegron25$21,306
JanuviaSitagliptin Phosphate19$20,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$54$306,856206 claims
Novo NordiskOzempic$39$162,393130 claims
PfizerEliquis$17$119,403113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Maitland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →